Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 509 clinical trials
None
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

This is a Phase Ib, open label, dose escalation study of spartalizumab + LAG525 in combination with NIR178, capmatinib, MCS110, or canakinumab, followed by a dose expansion in adult patients with advanced or metastatic TNBC. During the dose-escalation part of each treatment arm, patients will be treated with fixed doses …

adjuvant chemotherapy
estrogen
measurable disease
triple negative breast cancer
progesterone receptor
  • 44 views
  • 05 Aug, 2021
  • 13 locations
None
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

alone or paclitaxel and carboplatin in treating triple-negative breast cancer.

isolation procedure
absolute neutrophil count
triple-negative breast cancer
cyclophosphamide
epidermal growth factor receptor
  • 822 views
  • 23 Nov, 2021
  • 812 locations
None
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects happen when participants get these two drugs

HER2
breast cancer
erbb2
advanced breast cancer
stage iv breast cancer
  • 186 views
  • 28 Nov, 2021
  • 60 locations
None
Trilaciclib a CDK 4/6 Inhibitor in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or second-line treatment for locally advanced unresectable/metastatic TNBC.

triple negative breast cancer
HER2
progesterone receptor
progesterone
erbb2
  • 0 views
  • 28 Nov, 2021
  • 51 locations
None
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib Carelizumab Plus Nab-paclitaxel and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

and Apatinib, carelizumab plus nab-paclitaxel, and Nab-paclitaxel in Patients with Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer. Participants will be randomized in a 1:1:1

locally advanced breast cancer
apatinib
HER2
triple-negative breast cancer
advanced breast cancer
  • 0 views
  • 24 Jan, 2021
  • 1 location
None
A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

neoadjuvant therapy in participants with triple negative breast cancer (TNBC). Participants will be randomized in a 1:1 ratio to Arm A (camrelizumab +chemotherapy) or Arm B (placebo + chemotherapy).

  • 0 views
  • 27 Jan, 2021
  • 1 location
None
Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

first/second line treatment of metastatic or recurrent triple-negative breast cancer (TNBC).

HER2
triple-negative breast cancer
growth factor
estrogen
mammogram
  • 28 views
  • 24 Jan, 2021
  • 79 locations
None
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Study MO39874 is an open-label, phase IIIb, single arm, multicenter study conducted in participants with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer

metastasis
HER2
triple-negative breast cancer
adenocarcinoma
mammogram
  • 147 views
  • 28 Nov, 2021
  • 164 locations
None
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC

measurable disease
triple-negative breast cancer
paclitaxel
breast cancer
mammogram
  • 1388 views
  • 24 Nov, 2021
  • 335 locations
None
Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

adults with triple-negative breast cancer (TNBC) will also be assessed.

pemetrexed
mk-3475
antineoplastic
cancer
pembrolizumab
  • 284 views
  • 27 Nov, 2021
  • 16 locations